SG11202008971VA - Compositions and methods for treating severe constipation - Google Patents

Compositions and methods for treating severe constipation

Info

Publication number
SG11202008971VA
SG11202008971VA SG11202008971VA SG11202008971VA SG11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating severe
severe constipation
constipation
Prior art date
Application number
SG11202008971VA
Inventor
Brian K Hubbard
Michael H Serrano-Wu
Original Assignee
Anji Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anji Pharmaceuticals Inc filed Critical Anji Pharmaceuticals Inc
Publication of SG11202008971VA publication Critical patent/SG11202008971VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202008971VA 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation SG11202008971VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (1)

Publication Number Publication Date
SG11202008971VA true SG11202008971VA (en) 2020-10-29

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008971VA SG11202008971VA (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Country Status (16)

Country Link
US (2) US11224590B2 (en)
EP (1) EP3765012A4 (en)
JP (1) JP2021518431A (en)
KR (1) KR20200136428A (en)
CN (1) CN111936137B (en)
AU (1) AU2019234956A1 (en)
BR (1) BR112020018790A2 (en)
CA (1) CA3093970A1 (en)
EA (1) EA202092190A1 (en)
IL (1) IL277332A (en)
MX (1) MX2020009604A (en)
PE (1) PE20210158A1 (en)
PH (1) PH12020551468A1 (en)
SG (1) SG11202008971VA (en)
TW (1) TWI704917B (en)
WO (1) WO2019178492A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11224590B2 (en) 2018-03-16 2022-01-18 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation
KR20220052459A (en) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 Welding device having an electrode tab fixing member and Electrode tab welding method using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2402319T (en) * 2006-03-31 2017-12-11 Novartis Ag Dgat inhibitors
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
AU2011235301B2 (en) * 2010-03-30 2013-07-18 Novartis Ag Uses of DGAT1 inhibitors
US8518995B2 (en) * 2010-04-08 2013-08-27 Medicinova, Inc. Methods and compositions for the treatment of irritable bowel syndrome
AR083417A1 (en) * 2010-10-14 2013-02-21 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING AN INHIBITOR DGAT1
WO2013130370A2 (en) 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
MX2015002210A (en) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions.
CN114939156A (en) * 2014-01-09 2022-08-26 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
US11224590B2 (en) 2018-03-16 2022-01-18 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation

Also Published As

Publication number Publication date
EP3765012A4 (en) 2021-12-15
IL277332A (en) 2020-10-29
WO2019178492A1 (en) 2019-09-19
TW201944995A (en) 2019-12-01
CN111936137B (en) 2023-09-08
EP3765012A1 (en) 2021-01-20
MX2020009604A (en) 2023-01-25
PH12020551468A1 (en) 2021-09-01
AU2019234956A1 (en) 2020-10-01
CA3093970A1 (en) 2019-09-19
US20220193044A1 (en) 2022-06-23
PE20210158A1 (en) 2021-01-26
BR112020018790A2 (en) 2020-10-13
JP2021518431A (en) 2021-08-02
KR20200136428A (en) 2020-12-07
CN111936137A (en) 2020-11-13
US20190282549A1 (en) 2019-09-19
US11224590B2 (en) 2022-01-18
EA202092190A1 (en) 2020-11-19
TWI704917B (en) 2020-09-21
US11819495B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL269150A (en) Compositions and methods for treating cancer
IL288914A (en) Compositions and methods for treating cancer
IL286350A (en) Compositions and methods for treating cancer
IL274837A (en) Methods and compositions for treating cancers
IL271256A (en) Compositions and methods for treating tauopathies
IL269157A (en) Compositions and methods for treating cancer
IL285886A (en) Compositions and methods for treating laminopathies
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL280413A (en) Bismuth-thiol compositions and methods for treating wounds
SG11202012435UA (en) Compositions and methods for treating cancer
IL287982A (en) Compositions and methods for treating cancer
ZA202104870B (en) Methods and compositions for treating cancer
ZA202101342B (en) Compositions and methods for treating the eye
EP4025590A4 (en) Methods and compositions for treating cancer
IL277332A (en) Compositions and methods for treating severe constipation
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
IL285796A (en) Methods and compositions for treating
EP3781154A4 (en) Compositions and methods for treating renal injury
IL286153A (en) Methods and compositions for treating cancer
IL277463A (en) Compositions and methods for treating pruritus
IL272782A (en) Compositions and methods for treating cancer
EP3781945A4 (en) Compositions and methods for treating endometriosis
PT3810128T (en) Compositions for treating and/or preventing protein-aggregation diseases
EP3681520A4 (en) Compositions and methods for treating liver disease and dysfunction